Jérôme Ory1, Charline Mourgues2, Evelyne Raybaud3, Russell Chabanne4,5, Jean Christophe Jourdy6, Fabien Belard6, Renaud Guérin7, Bernard Cosserant8, Jean Sébastien Faure5, Laure Calvet9, Bruno Pereira2, Dominique Guelon5, Ousmane Traore3, Laurent Gerbaud10. 1. Hygiène Hospitalière, Centre Hospitalier Universitaire de Clermont-Ferrand, 58 Rue Montalembert, Clermont-Ferrand, Auvergne Rhône-Alpes, France. jerome.ory@hotmail.fr. 2. Direction Recherche Clinique Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, France. 3. Hygiène Hospitalière, Centre Hospitalier Universitaire de Clermont-Ferrand, 58 Rue Montalembert, Clermont-Ferrand, Auvergne Rhône-Alpes, France. 4. Réanimation Neurochirurgicale, CHU Clermont-Ferrand, Clermont-Ferrand, France. 5. Réanimation Médico-Chirurgicale, CHU Gabriel Montpied, Clermont-Ferrand, France. 6. Département de l'Information Médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France. 7. Réanimation Médico-Chirurgicale Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France. 8. Réanimation Cardio Vasculaire, CHU Clermont-Ferrand, Clermont-Ferrand, France. 9. Réanimation Médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France. 10. Santé Publique, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Abstract
OBJECTIVES: Ventilator-associated pneumonia (VAP) is the most frequent hospital-acquired infections in intensive care units (ICU). In the bundle of care to prevent the VAP, the oral care is very important strategies, to decrease the oropharyngeal bacterial colonization and presence of causative bacteria of VAP. In view of the paucity of medical economics studies, our objective was to determine the cost of implementing this oral care program for preventing VAP. MATERIALS AND METHODS: In five ICUs, during period 1, caregivers used a foam stick for oral care and, during period 2, a stick and tooth brushing with aspiration. Budgetary effect of the new program from the hospital's point of view was analyzed for both periods. The costs avoided were calculated from the incidence density of VAP (cases per 1000 days of intubation). The cost study included device cost, benefit lost, and ICU cost (medication, employer and employee contributions, blood sample analysis…). RESULTS: A total of 2030 intubated patients admitted to the ICUs benefited from oral care. The cost of implementing the study protocol was estimated to be €11,500 per year. VAP rates decreased significantly between the two periods (p1 = 12.8% and p2 = 8.5%, p = 0.002). The VAP revenue was ranged from €28,000 to €45,000 and the average cost from €39,906 to €42,332. The total cost assessment calculated was thus around €1.9 million in favor of the new oral care program. CONCLUSION AND CLINICAL RELEVANCE: Our study showed that the implementation of a simple strategy improved the quality of patient care is economically viable. TRIAL REGISTRATION: NCT02400294.
OBJECTIVES: Ventilator-associated pneumonia (VAP) is the most frequent hospital-acquired infections in intensive care units (ICU). In the bundle of care to prevent the VAP, the oral care is very important strategies, to decrease the oropharyngeal bacterial colonization and presence of causative bacteria of VAP. In view of the paucity of medical economics studies, our objective was to determine the cost of implementing this oral care program for preventing VAP. MATERIALS AND METHODS: In five ICUs, during period 1, caregivers used a foam stick for oral care and, during period 2, a stick and tooth brushing with aspiration. Budgetary effect of the new program from the hospital's point of view was analyzed for both periods. The costs avoided were calculated from the incidence density of VAP (cases per 1000 days of intubation). The cost study included device cost, benefit lost, and ICU cost (medication, employer and employee contributions, blood sample analysis…). RESULTS: A total of 2030 intubated patients admitted to the ICUs benefited from oral care. The cost of implementing the study protocol was estimated to be €11,500 per year. VAP rates decreased significantly between the two periods (p1 = 12.8% and p2 = 8.5%, p = 0.002). The VAP revenue was ranged from €28,000 to €45,000 and the average cost from €39,906 to €42,332. The total cost assessment calculated was thus around €1.9 million in favor of the new oral care program. CONCLUSION AND CLINICAL RELEVANCE: Our study showed that the implementation of a simple strategy improved the quality of patient care is economically viable. TRIAL REGISTRATION: NCT02400294.
Authors: Eyal Zimlichman; Daniel Henderson; Orly Tamir; Calvin Franz; Peter Song; Cyrus K Yamin; Carol Keohane; Charles R Denham; David W Bates Journal: JAMA Intern Med Date: 2013 Dec 9-23 Impact factor: 21.873
Authors: Davi Francisco Casa Blum; José Augusto Santos da Silva; Fernando Martins Baeder; Álvaro Della Bona Journal: Rev Bras Ter Intensiva Date: 2018-09-03